Skip to main content

Table 1 Baseline characteristics of patients in the ascend group and the stable group

From: Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Characteristics Ascend group (n, %) Stable group (n, %) P
Gender    0.346
 Male 30 (49.2) 7 (36.8)  
 Female 31 (50.8) 12 (63.2)  
Age (median, range) 62 (40~84) 69 (40~84) 0.362
Body weight loss    1.000
 <5 % 58 (95.1) 19 (100.0)  
 ≥5 % 3 (4.9) 0 (0.0)  
Smoking status    0.401
 Never-smokers 41 (67.2) 15 (78.9)  
 Smokers 20 (32.8) 4 (21.1)  
ECOG PS    1.000
 0~1 58 (95.1) 18 (94.7)  
 ≥2 3 (4.9) 1 (5.3)  
Pathology    1.000
 Adenocarcinoma 58 (95.1) 18 (94.7)  
 Non-adenocarcinoma 3 (4.9) 1 (5.3)  
Clinical stage    1.000
 IIIB 1 (1.6) 0 (0.0)  
 IV 60 (98.4) 19 (100.0)  
Line of EGFR-TKI    0.371
 First-line 36 (59.0) 9 (47.4)  
 ≥Second-line 25 (41.0) 10 (52.6)  
EGFR-TKI    0.946
 Erlotinib 23 (37.7) 7 (36.8)  
 Gefitinib 38 (62.3) 12 (63.2)  
Basic level of plasma L858R mutation (median, range) 20.0 (0.97~109.43) 27.45 (3.56~112.9) 0.184
  1. ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor